• Tranexamic Acid (TXA),YCHEMIR,Tranexamic Acid (TXA)
  • Tranexamic Acid (TXA),YCHEMIR,Tranexamic Acid (TXA)

Tranexamic Acid (TXA)

No.1197-18-8

Tranexamic Acid (TXA, CAS 1197-18-8) is high‑purity white crystalline powder, an antifibrinolytic pharmaceutical API and widely‑adopted skin‑brightening cosmetic raw‑material for pharmaceutical, cosmetic and biochemical‑research sectors.

Download
View all downloads
  • Tranexamic Acid (TXA),YCHEMIR,Tranexamic Acid (TXA)

Description

Chemical Name: Tranexamic Acid (TXA)

Synonyms: trans-4-(Aminomethyl)cyclohexanecarboxylic acid, AMCA, TXA, Transamic acid

CAS NO: 1197-18-8

EINECS Number: 214-818-2

Formula: C₈H₁₅NO₂

Molecular Weight: 157.21 g/mol

Product Type: Antifibrinolytic pharmaceutical raw material, cosmetic brightening functional ingredient, biochemical research reagent

Item

Specification

Appearance

White to off‑white crystalline powder

Purity

≥99.0 %

Loss on Drying

≤0.5 %

Melting Point

>300 ℃

Density (25 ℃, g/cm3)

1.10‑1.17 g/cm³

Flash Point

135.4 ℃

Description:

Tranexamic Acid (CAS 1197‑18‑8, TXA) is a synthetic lysine‑derived zwitterionic amino‑acid compound, appearing as white‑to‑off‑white nearly odourless crystalline powder under ambient conditions. It acts as a competitive plasminogen‑activation inhibitor, suppressing fibrin breakdown and exerting antifibrinolytic haemostatic effects. In cosmetic formulations, it blocks melanin‑stimulating signal pathways to deliver skin brightening and improvement of post‑inflammatory hyperpigmentation and chloasma.

The substance is slightly light‑sensitive; light‑proof sealed storage is required. It exhibits excellent water solubility and forms neutral aqueous solutions. Qualified batches contain no harmful heavy‑metal impurities, suitable for pharmaceutical API production, cosmetic raw‑material formulation and biochemical fundamental research.

Core advantages: Excellent water‑solubility, stable in neutral aqueous systems, dual‑use for pharmaceutical and cosmetic applications, low irritation at recommended dosage, abundant published safety and pharmacological data.

Application:

  • Pharmaceutical Industry: Antifibrinolytic active pharmaceutical ingredient for oral tablets and injectable solutions. Indicated for prevention and management of bleeding associated with systemic or local fibrinolysis, including surgical haemorrhage, menorrhagia, trauma bleeding, dental and obstetric‑gynaecological haemorrhage events.
  • Cosmetic Industry: Functional brightening raw material for serums, lotions, creams and facial‑mask systems; inhibits melanin hyper‑pigmentation, mitigates chloasma and post‑inflammatory pigmentation.
  • Biochemical & Laboratory Research: Reference reagent for fibrinolysis, haematology and pharmacological mechanism studies.
  • Fine‑Chemical Synthesis: Building‑block intermediate for amino‑acid derivative synthesis and modification.

Packaging: Lab scale: sealed amber glass bottle / aluminum‑foil bag (10 g / 50 g /100 g /500 g); bulk: 1 kg /5 kg /25 kg light‑proof sealed composite plastic drum. Custom packaging available upon request.

Storage: Store in cool, dry, dust‑free warehouse. Keep containers tightly closed and protected from direct sunlight and UV radiation. Recommended storage temperature: 5‑25 ℃. Keep away from heat sources, strong oxidants, concentrated acids and bases. Inert‑gas sealed storage is preferred for long‑term preservation.

Shelf Life: 36 months for unopened original sealed packages under standard storage conditions. Immediately reseal after opening and consume within 3 months to assure purity and stability.